Drug name - Tadliq

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11382917 CMP DEV LLC Liquid oral formulations for tadalafil
Dec, 2038

(16 years from now)

Drugs and Companies using TADALAFIL ingredient

Market Authorisation Date: 17 June, 2022

Treatment: Tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
20MG/5ML SUSPENSION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in